The dosimetry and imaging layer
for radiopharmaceutical therapy.
A coherent platform for absorbed dose verification, imaging analytics, and clinical workflow intelligence — built for the operational realities of modern RPT programs.
A coherent pipeline from scan to insight.
Every RPT case, in one operational view.
A production-grade case list treats each RPT cycle as a coordinated clinical workflow — not a sequence of disconnected studies. Status, ownership, and cycle context live in one place.
- Agent-aware routing — Lu-177 PSMA, Ac-225, and emerging isotopes
- Cycle-over-cycle visibility for longitudinal programs
- Role-based review states: physicist, physician, sign-off
- Full auditability for regulated operations
Active cases
| ID | Patient | Cycle | Imaging | Dose (Gy) | Status |
|---|---|---|---|---|---|
| 04291 | R. Hensley Lu-177 PSMA | C3 / 6 | SPECT/CT · t+24h | 8.4 | Awaiting MD |
| 04288 | M. Okafor Lu-177 PSMA | C2 / 6 | SPECT/CT · t+48h | 6.1 | Signed off |
| 04285 | J. Park Lu-177 PSMA | C4 / 6 | SPECT/CT · t+72h | 5.2 | In review |
| 04281 | A. Mendez Lu-177 PSMA | C1 / 6 | Pending | — | Ingesting |
| 04276 | S. Rivera Lu-177 PSMA | C2 / 6 | SPECT/CT · t+24h | 7.0 | Signed off |
| 04272 | D. Chen Lu-177 PSMA | C3 / 6 | SPECT/CT · t+48h | 6.7 | Awaiting MD |
Lesion L1 · Pelvic
Organs at risk
Cycle context
Voxel-level dosimetry you can trust and review.
A quantitative viewer built for dose verification — not a repurposed radiology PACS. Fused isodose visualization, organ-at-risk tracking, and cycle-over-cycle context, all in one inspectable frame.
- Voxel-level Monte Carlo and kernel-based dosimetry
- Lesion- and organ-level dose metrics (Dmax, Dmean, D90)
- Side-by-side cycle comparison
- Full provenance on every computed number
Clinically literate reports, not PDF exports.
RadFox reports are designed around how nuclear medicine teams actually document, review, and hand off cases. Structured data first — human-readable narrative assembled on top.
- Structured dose report with per-lesion, per-organ detail
- AI-assisted narrative summary, always reviewable
- Longitudinal context built in, not stapled on
- Exportable to EHR and trial databases
Post-therapy dose verification
Summary
Absorbed dose estimates within expected range for cycle 3. Pelvic lesion L1 showed continued favorable uptake with mean dose of 6.2 Gy (D90 5.1). Kidney exposure remains cumulatively within safety thresholds.
Target lesions
| ROI | Volume | Dmean | Dmax | Δ vs C2 |
|---|---|---|---|---|
| L1 · Pelvic | 12.4 mL | 6.2 Gy | 8.4 Gy | +11% |
| L2 · Retroperitoneal | 4.1 mL | 3.8 Gy | 5.0 Gy | +6% |
Organs at risk · cumulative
| Organ | This cycle | Cumulative | Margin |
|---|---|---|---|
| Kidney R | 2.8 Gy | 8.1 Gy | within |
| Kidney L | 2.6 Gy | 7.6 Gy | within |
| Parotid | 0.9 Gy | 2.7 Gy | within |
| Marrow | 0.4 Gy | 1.2 Gy | within |
Built to the standard clinical systems require.
Quality-system ready
Designed from day one around the operational realities of regulated medical software development and deployment.
DICOM & HL7-native
Ingest SPECT/CT and PET/CT studies, route patient and protocol metadata, and export to EHR pipelines.
On-prem or private cloud
Deployable inside institutional environments without moving PHI across boundaries that shouldn't be crossed.
Reviewable AI
Segmentation and narrative assist act as copilots for trained staff — always transparent, always reviewable.
Auditable by default
Every computation, every segmentation, every sign-off has provenance — because regulated clinical work demands it.
Scanner-agnostic
Built for the real heterogeneity of multi-site, multi-vendor imaging — not a single reference scanner.
Design partners wanted.
RadFox is actively engaging design partners among academic cancer centers, radiopharma developers, and clinical physics teams. Early partners help shape what this platform becomes.